<DOC>
	<DOCNO>NCT00337116</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled study , clinical trail design evaluate efficacy safety superiority intravenous bolus isosorbide dinitrate relief acute anginal pain episode acute coronary syndrome patient comparison usual manner S/L isosorbide dinitrate .</brief_summary>
	<brief_title>Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate Relief Acute Anginal Episodes Acute Coronary Syndrome ( ACS ) Patients</brief_title>
	<detailed_description>Analgesia important element management ACS patient . Pain contributes heighten sympathetic activity particularly prominent period acute STEMI , NSTEMI unstable angina consequentially cause elevation tissue oxygen demand . Control cardiac pain typically accomplished combination oxygen , analgesic ( e.g . morphine ) beta blocker agent primarily nitrate . Sublingual nitrate currently guideline recommend preparation instant relief brief episodes pain . In patient prolonged period wax wan chest pain , drip intravenous nitrate may benefit control symptom correct ischemia . Intravenous nitrate also indicate treatment acute decompensated CHF patient pulmonary edema , nevertheless current treatment patient edema repeat intravenous bolus sublingual isosorbide dinitrate , follow continuous drip . Although hard data intravenous high-dose nitrate relief acute anginal pain episode , clinical impression method excellent . Intravenous bolus isosorbide dinitrate hospital set provide immediate , accurate ( bioavailability ) easily control modality provide nitrate . Since intravenous bolus isosorbide dinitrate standard care acute anginal pain episode ICCU time , well design comparative study two method would help become guideline matter choice case .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1 . Age &gt; 18 year old . 2 . Admission ICCU ACS ( nonST elevation acute coronary syndrome 24 hour ST elevation myocardial infarction ) . 3 . Presence ischemic symptom ( ≥5 minute ) hospitalization . 4 . Pain assessment 3 10 Visual Analog Scale ( VAS ) 1 dynamic ECG finding ( ST segment deviation ≥0.05 mV T wave inversion ≥ 0.3 mV ) 5 . Willing able provide write informed consent accord regulation Ministry Health Helsinki committee instruction . 1 . Patient meet follow criterion exclude study : 2 . Persistent STsegment elevation ≥ 1 mV 2 contiguous lead new LBBB . 3 . Acute pulmonary edema 4 . Sepsis 5 . Sustained systolic blood pressure &lt; 90 mm Hg evidence cardiogenic shock 6 . Pregnant woman 7 . Use randomization agent know enhance efficacy nitrate . 8 . Clinically significant aortic stenosis 9 . Cr &gt; 2 mg/dL 10 . Participation another trial investigational drug device randomization . 11 . Allergy sensitivity nitatrate compound 12 . Acute episode cerebrovascular attack 13 . Inability comply protocol followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>